CVKD — Cadrenal Therapeutics Cashflow Statement
0.000.00%
- $28.03m
- $18.02m
Annual cashflow statement for Cadrenal Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -6.71 | -8.36 | -10.7 |
Depreciation | |||
Non-Cash Items | 4.9 | 4.68 | 1.42 |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | 0.608 | 0.144 | 1.87 |
Change in Prepaid Expenses | |||
Change in Other Assets | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Net Change in Other Assets & Liabilities | |||
Cash from Operating Activities | -1.2 | -3.53 | -7.36 |
Other Investing Cash Flow Items | -0.002 | -0.003 | -0.007 |
Purchase of Investments | |||
Cash from Investing Activities | -0.002 | -0.003 | -0.007 |
Financing Cash Flow Items | — | — | -0.338 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 1.24 | 11.9 | 8.98 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | 0.033 | 8.37 | 1.62 |